Cargando…

Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guérin

BACKGROUND AND OBJECTIVES: To evaluate the long-term prognostic value of the combination of the EORTC risk calculator and proapoptotic, antiapoptotic, proliferation, and invasiveness molecular markers in predicting the outcome of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC)...

Descripción completa

Detalles Bibliográficos
Autores principales: Alkhateeb, Sultan S., Neill, Mischel, Bar-Moshe, Sas, Rhijn, Bas Van, Kakiashvili, David M., Fleshner, Neil, Jewett, Michael, Petein, Michel, Schulman, Claude, Hanna, Sally, Bostrom, Peter J., Roumeguere, Thierry, Shariat, Shahrokh F., Rorive, Sandrine, Zlotta, Alexandre R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3183702/
https://www.ncbi.nlm.nih.gov/pubmed/21976923
http://dx.doi.org/10.4103/0974-7796.84954
_version_ 1782213032723611648
author Alkhateeb, Sultan S.
Neill, Mischel
Bar-Moshe, Sas
Rhijn, Bas Van
Kakiashvili, David M.
Fleshner, Neil
Jewett, Michael
Petein, Michel
Schulman, Claude
Hanna, Sally
Bostrom, Peter J.
Roumeguere, Thierry
Shariat, Shahrokh F.
Rorive, Sandrine
Zlotta, Alexandre R.
author_facet Alkhateeb, Sultan S.
Neill, Mischel
Bar-Moshe, Sas
Rhijn, Bas Van
Kakiashvili, David M.
Fleshner, Neil
Jewett, Michael
Petein, Michel
Schulman, Claude
Hanna, Sally
Bostrom, Peter J.
Roumeguere, Thierry
Shariat, Shahrokh F.
Rorive, Sandrine
Zlotta, Alexandre R.
author_sort Alkhateeb, Sultan S.
collection PubMed
description BACKGROUND AND OBJECTIVES: To evaluate the long-term prognostic value of the combination of the EORTC risk calculator and proapoptotic, antiapoptotic, proliferation, and invasiveness molecular markers in predicting the outcome of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) treated with intravesical Bacille Calmette-Guérin (BCG) therapy. MATERIALS AND METHODS: This study included 42 patients accrued prospectively presenting with intermediate- to high-risk NMIBC (high-grade T1 tumors or multiple rapidly recurrent tumors refractory to intravesical chemotherapy) treated with transurethral resection (TUR) and BCG. TUR samples were analyzed for the molecular markers p53, p21 waf1/cip, Bcl-2, CyclinD1, and metallothionein 9 (MMP9) using immunohistochemistry. Frequency of positivity, measured as a percentage, was assessed alone or in combination with EORTC risk calculator, for interaction with outcome in terms of recurrence and progression using univariate analysis and Kaplan-Meier survival curves. RESULTS: Median follow-up was 88 months (mean, 99; range, 14-212 months). The overall recurrence rate was 61.9% and progression rate was 21.4%. In univariate analysis, CyclinD1 and EORTC risk groups were significantly associated with recurrence (P value 0.03 and 0.02, respectively), although none of the markers showed a correlation to progression. In combining EORTC risk groups to markers expression status, high-risk group associated with positive MMP9, Bcl-2, CyclinD1, or p21 was significantly correlated to tumor recurrence (log rank P values <0.001, 0.03, 0.02, and 0.006, respectively) and when associated with positive MMP9 or p21, it was significantly correlated to progression (log rank P values 0.01 and 0.04, respectively). CONCLUSION: Molecular markers have a long-term prognostic value when combined with EORTC scoring system and they may be used to improve the predictive accuracy of currently existing scoring system. Larger series are needed to confirm these findings.
format Online
Article
Text
id pubmed-3183702
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Medknow Publications
record_format MEDLINE/PubMed
spelling pubmed-31837022011-10-05 Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guérin Alkhateeb, Sultan S. Neill, Mischel Bar-Moshe, Sas Rhijn, Bas Van Kakiashvili, David M. Fleshner, Neil Jewett, Michael Petein, Michel Schulman, Claude Hanna, Sally Bostrom, Peter J. Roumeguere, Thierry Shariat, Shahrokh F. Rorive, Sandrine Zlotta, Alexandre R. Urol Ann Original Article BACKGROUND AND OBJECTIVES: To evaluate the long-term prognostic value of the combination of the EORTC risk calculator and proapoptotic, antiapoptotic, proliferation, and invasiveness molecular markers in predicting the outcome of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) treated with intravesical Bacille Calmette-Guérin (BCG) therapy. MATERIALS AND METHODS: This study included 42 patients accrued prospectively presenting with intermediate- to high-risk NMIBC (high-grade T1 tumors or multiple rapidly recurrent tumors refractory to intravesical chemotherapy) treated with transurethral resection (TUR) and BCG. TUR samples were analyzed for the molecular markers p53, p21 waf1/cip, Bcl-2, CyclinD1, and metallothionein 9 (MMP9) using immunohistochemistry. Frequency of positivity, measured as a percentage, was assessed alone or in combination with EORTC risk calculator, for interaction with outcome in terms of recurrence and progression using univariate analysis and Kaplan-Meier survival curves. RESULTS: Median follow-up was 88 months (mean, 99; range, 14-212 months). The overall recurrence rate was 61.9% and progression rate was 21.4%. In univariate analysis, CyclinD1 and EORTC risk groups were significantly associated with recurrence (P value 0.03 and 0.02, respectively), although none of the markers showed a correlation to progression. In combining EORTC risk groups to markers expression status, high-risk group associated with positive MMP9, Bcl-2, CyclinD1, or p21 was significantly correlated to tumor recurrence (log rank P values <0.001, 0.03, 0.02, and 0.006, respectively) and when associated with positive MMP9 or p21, it was significantly correlated to progression (log rank P values 0.01 and 0.04, respectively). CONCLUSION: Molecular markers have a long-term prognostic value when combined with EORTC scoring system and they may be used to improve the predictive accuracy of currently existing scoring system. Larger series are needed to confirm these findings. Medknow Publications 2011 /pmc/articles/PMC3183702/ /pubmed/21976923 http://dx.doi.org/10.4103/0974-7796.84954 Text en © Urology Annals http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Alkhateeb, Sultan S.
Neill, Mischel
Bar-Moshe, Sas
Rhijn, Bas Van
Kakiashvili, David M.
Fleshner, Neil
Jewett, Michael
Petein, Michel
Schulman, Claude
Hanna, Sally
Bostrom, Peter J.
Roumeguere, Thierry
Shariat, Shahrokh F.
Rorive, Sandrine
Zlotta, Alexandre R.
Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guérin
title Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guérin
title_full Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guérin
title_fullStr Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guérin
title_full_unstemmed Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guérin
title_short Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guérin
title_sort long-term prognostic value of the combination of eortc risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical bacille calmette-guérin
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3183702/
https://www.ncbi.nlm.nih.gov/pubmed/21976923
http://dx.doi.org/10.4103/0974-7796.84954
work_keys_str_mv AT alkhateebsultans longtermprognosticvalueofthecombinationofeortcriskgroupcalculatorandmolecularmarkersinnonmuscleinvasivebladdercancerpatientstreatedwithintravesicalbacillecalmetteguerin
AT neillmischel longtermprognosticvalueofthecombinationofeortcriskgroupcalculatorandmolecularmarkersinnonmuscleinvasivebladdercancerpatientstreatedwithintravesicalbacillecalmetteguerin
AT barmoshesas longtermprognosticvalueofthecombinationofeortcriskgroupcalculatorandmolecularmarkersinnonmuscleinvasivebladdercancerpatientstreatedwithintravesicalbacillecalmetteguerin
AT rhijnbasvan longtermprognosticvalueofthecombinationofeortcriskgroupcalculatorandmolecularmarkersinnonmuscleinvasivebladdercancerpatientstreatedwithintravesicalbacillecalmetteguerin
AT kakiashvilidavidm longtermprognosticvalueofthecombinationofeortcriskgroupcalculatorandmolecularmarkersinnonmuscleinvasivebladdercancerpatientstreatedwithintravesicalbacillecalmetteguerin
AT fleshnerneil longtermprognosticvalueofthecombinationofeortcriskgroupcalculatorandmolecularmarkersinnonmuscleinvasivebladdercancerpatientstreatedwithintravesicalbacillecalmetteguerin
AT jewettmichael longtermprognosticvalueofthecombinationofeortcriskgroupcalculatorandmolecularmarkersinnonmuscleinvasivebladdercancerpatientstreatedwithintravesicalbacillecalmetteguerin
AT peteinmichel longtermprognosticvalueofthecombinationofeortcriskgroupcalculatorandmolecularmarkersinnonmuscleinvasivebladdercancerpatientstreatedwithintravesicalbacillecalmetteguerin
AT schulmanclaude longtermprognosticvalueofthecombinationofeortcriskgroupcalculatorandmolecularmarkersinnonmuscleinvasivebladdercancerpatientstreatedwithintravesicalbacillecalmetteguerin
AT hannasally longtermprognosticvalueofthecombinationofeortcriskgroupcalculatorandmolecularmarkersinnonmuscleinvasivebladdercancerpatientstreatedwithintravesicalbacillecalmetteguerin
AT bostrompeterj longtermprognosticvalueofthecombinationofeortcriskgroupcalculatorandmolecularmarkersinnonmuscleinvasivebladdercancerpatientstreatedwithintravesicalbacillecalmetteguerin
AT roumeguerethierry longtermprognosticvalueofthecombinationofeortcriskgroupcalculatorandmolecularmarkersinnonmuscleinvasivebladdercancerpatientstreatedwithintravesicalbacillecalmetteguerin
AT shariatshahrokhf longtermprognosticvalueofthecombinationofeortcriskgroupcalculatorandmolecularmarkersinnonmuscleinvasivebladdercancerpatientstreatedwithintravesicalbacillecalmetteguerin
AT rorivesandrine longtermprognosticvalueofthecombinationofeortcriskgroupcalculatorandmolecularmarkersinnonmuscleinvasivebladdercancerpatientstreatedwithintravesicalbacillecalmetteguerin
AT zlottaalexandrer longtermprognosticvalueofthecombinationofeortcriskgroupcalculatorandmolecularmarkersinnonmuscleinvasivebladdercancerpatientstreatedwithintravesicalbacillecalmetteguerin